Clover Health Investments financials
$4.33−0.12%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $1.92B | $1.37B | $1.26B | $1.10B | $1.47B |
| Gross profit | $355.9M | $364.8M | $256.0M | $103.5M | -$79.2M |
| Gross margin | 18.5% | 26.6% | 20.3% | 9.4% | −5.4% |
| Operating income | -$85.5M | -$45.7M | -$205.3M | -$286.7M | -$637.0M |
| Net income | -$85.5M | -$43.0M | -$213.4M | -$339.6M | -$587.8M |
| Net margin | −4.4% | −3.1% | −16.9% | −31.0% | −39.9% |
| Diluted EPS | $-0.17 | $-0.09 | $-0.44 | $-0.71 | $-1.42 |
| EBITDA | -$85.7M | -$46.7M | -$181.1M | -$287.0M | -$635.5M |
| Operating cash flow | -$66.9M | $34.8M | -$144.7M | -$203.9M | -$282.3M |
| Free cash flow | -$69.0M | $33.3M | -$145.2M | -$208.4M | -$283.0M |
| Diluted shares | 512.0M | 490.0M | 482.2M | 476.2M | 412.9M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $78.3M | $194.5M | $116.4M | $103.8M | $300.0M |
| Short-term investments | $42.0M | $27.0M | $119.8M | $231.0M | $315.3M |
| Total debt | $153.3M | $156.4M | $137.1M | $364.0M | $158.5M |
| Total assets | $541.0M | $580.7M | $570.7M | $808.6M | $950.8M |
| Total liabilities | $232.3M | $239.6M | $284.3M | $451.7M | $411.5M |
| Shareholders' equity | $308.7M | $341.1M | $286.4M | $356.9M | $539.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology